SWOG Cancer Research Network: all 339 studies

Page 1 of 4. Open to participants first (37), then studies with results posted, then the rest; newest registration first within each.

• Adding Capivasertib to Standard Treatment in HR Positive, HER2 Negative Metastatic Breast Cancer Based on ctDNA TestingNot yet recruitingNCT07802626Phase 3
• Testing Mosunetuzumab Alone, With Zanubrutinib, or With Polatuzumab Vedotin for Treating Marginal Zone Lymphoma That Came Back or Didn't Get Better With TreatmentNot yet recruitingNCT07638722Phase 2
• Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More TreatmentNot yet recruitingNCT07636564Phase 2
• Testing Short-Course Radiation Versus Standard-Course Radiation for Soft Tissue Sarcomas That Need Surgery and RadiationRecruitingNCT07615049Phase 3
• Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at DiagnosisRecruitingNCT07578116Phase 3
• Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell CountsNot yet recruitingNCT07498205Phase 4
• Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial)RecruitingNCT07393555Phase 2
• Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney CancerRecruitingNCT07383441Phase 3
• Testing an Educational Program to Improve Goals of Care Conversations Between Patients and Their Care TeamsRecruitingNCT07278739Not applicable
• Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID TrialRecruitingNCT07220187Phase 3
• Combined Amivantamab, Carboplatin and Paclitaxel in Unresectable Locally Recurrent or Metastatic Head and Neck CancerEnrolling by invitationNCT07062354Phase 2
• Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer SurvivorsRecruitingNCT07018869Phase 3
• Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS MutationsRecruitingNCT06998940Phase 3
• Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic FistulaRecruitingNCT06807437Phase 3
• Adding Asciminib to Usual Treatment for Adults With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic LeukemiaEnrolling by invitationNCT06773936Phase 2
• Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM StudyRecruitingNCT06769126Phase 2
• Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)RecruitingNCT06616584Phase 2/3
• Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the BodyRecruitingNCT06470243Phase 3
• Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)RecruitingNCT06116682Phase 2
• Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)RecruitingNCT06031688Phase 2
• Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL AmyloidosisRecruitingNCT06022939Phase 3
• Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast CancerRecruitingNCT05929768Phase 3
• Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to TreatmentRecruitingNCT05890352Phase 2
• Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene MutationRecruitingNCT05806515Phase 2
• Comparing Cooling and/or Compression Approaches of Limbs for Prevention of Chemotherapy-Induced Peripheral NeuropathyRecruitingNCT05642611Phase 3
• Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)RecruitingNCT05642572Phase 2
• Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaRecruitingNCT05633615Phase 2
• Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable TreatmentRecruitingNCT05561387Phase 3
• Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine TumorsRecruitingNCT05040360Phase 2
• Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid TumorsRecruitingNCT04871542
• A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain MetastasesRecruitingNCT04511013Phase 2
• Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE TrialRecruitingNCT04510597Phase 3
• Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel CancersRecruitingNCT04205968Phase 2
• Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung CancerRecruitingNCT03851445Phase 2/3
• S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast CancerRecruitingNCT03723928Not applicable
• Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate CancerRecruitingNCT03678025Phase 3
• S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac ToxicityRecruitingNCT03418961Phase 3
• Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL)TerminatedNCT04871529Phase 2Results posted
• Testing Diet Intervention Versus Non-Diet Intervention for Management of Bowel Symptoms in Rectal Cancer SurvivorsCompletedNCT04205955Phase 2Results posted
• S1916 Digital Medicine Program for Pain Control in Cancer PatientsTerminatedNCT04194528Not applicableResults posted
• Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)CompletedNCT04173507Phase 2Results posted
• Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)CompletedNCT03971474Phase 2Results posted
• Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With CancerActive, not recruitingNCT03939481Results posted
• Prophylactic Antiviral Therapy in Patients With Current or Past Hepatitis B Virus Infection Receiving Anti-Cancer Therapy for Solid TumorsTerminatedNCT03887702Phase 3Results posted
• Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)CompletedNCT03845296Phase 2Results posted
• Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract CancersCompletedNCT03768414Phase 3Results posted
• Nutrition Therapy in Improving Immune System in Patients With Bladder Cancer That Can Be Removed by SurgeryActive, not recruitingNCT03757949Phase 3Results posted
• Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by SurgeryCompletedNCT03694002Phase 2Results posted
• Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid LeukemiaActive, not recruitingNCT03654768Phase 2Results posted
• Lung-MAP S1400K: c-MET PositiveCompletedNCT03574753Phase 2Results posted
• S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary AmyloidosisCompletedNCT03499808Phase 2Results posted
• Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung CancerCompletedNCT03377556Phase 2Results posted
• Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung CancerCompletedNCT03373760Phase 2Results posted
• S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by SurgeryCompletedNCT03365882Phase 2Results posted
• Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung CancerCompletedNCT02965378Phase 2/3Results posted
• Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker MatchesTerminatedNCT02926638Phase 2/3Results posted
• Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching BiomarkersActive, not recruitingNCT02785952Phase 3Results posted
• Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung CancerCompletedNCT02785939Phase 2/3Results posted
• Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker MatchesCompletedNCT02785913Phase 2Results posted
• Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching BiomarkersCompletedNCT02766335Phase 2/3Results posted
• S1417CD Financial Impact Assessment Tool in Patients With Metastatic Colorectal CancerCompletedNCT02728804Results posted
• S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)CompletedNCT02728596Not applicableResults posted
• S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by SurgeryCompletedNCT02562716Phase 2Results posted
• S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung CancerCompletedNCT02438722Phase 2/3Results posted
• S1316, Surgery or Non-Surgical Management in Treating Patients With Intra-Abdominal Cancer and Bowel ObstructionCompletedNCT02270450Not applicableResults posted
• S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder CancerCompletedNCT02177695Phase 2Results posted
• S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal CancerCompletedNCT02164916Phase 2Results posted
• Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung CancerCompletedNCT02154490Results posted
• S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast CancerTerminatedNCT02137837Phase 3Results posted
• S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After CrizotinibTerminatedNCT02134912Phase 2Results posted
• S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic CancerCompletedNCT01959139Phase 1/2Results posted
• S1204, Viral Screening in Newly Diagnosed Cancer PatientsCompletedNCT01946516Results posted
• S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute LeukemiaCompletedNCT01925131Phase 1Results posted
• S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory MyelomaCompletedNCT01903811Phase 2Results posted
• S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate CancerCompletedNCT01809691Phase 3Results posted
• S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast CancerActive, not recruitingNCT01674140Phase 3Results posted
• S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple MyelomaCompletedNCT01668719Phase 1/2Results posted
• S1202: Duloxetine Hydrochloride for Muscle/Joint Pain in Early-Stage Breast Cancer Receiving Hormone TherapyCompletedNCT01598298Phase 3Results posted
• S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction CancerCompletedNCT01498289Phase 2Results posted
• S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell LymphomaCompletedNCT01412879Phase 2Results posted
• S0927:Omega3-Fatty Acid Supp in Treating Muscle&Bone Pain&Stiffness in Pts W/Stg I,II,III Brst Canc Rec'v Hormone ThpyCompletedNCT01385137Phase 3Results posted
• S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell LymphomaCompletedNCT01359592Phase 2Results posted
• S1014 Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone TherapyCompletedNCT01309672Phase 2Results posted
• S1011 Standard or Extended Pelvic Lymphadenectomy in Treating Patients Undergoing Surgery for Invasive Bladder CancerCompletedNCT01224665Not applicableResults posted
• S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone SurgeryCompletedNCT01120249Phase 3Results posted
• S0916, MLN1202 in Treating Patients With Bone MetastasesCompletedNCT01015560Phase 2Results posted
• S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung CancerTerminatedNCT00946712Phase 3Results posted
• S0910 Epratuzumab, Cytarabine, and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic LeukemiaCompletedNCT00945815Phase 2Results posted
• S0904: Docetaxel With or Without Vandetanib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerCompletedNCT00872989Phase 2Results posted
• S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast CancerCompletedNCT00856492Phase 2Results posted
• S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid LeukemiaCompletedNCT00840177Phase 2Results posted
• S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin LymphomaCompletedNCT00822120Phase 2Results posted
• S0720: Adjuvant Therapy Based on Gene Expression in Stage IA and IB Non-Small Cell Lung CancerCompletedNCT00792701Phase 2Results posted
• S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile DuctCompletedNCT00789958Phase 2Results posted
• S0000B: Vitamin E and/or Selenium in Preventing Cataract and Age-Related Macular Degeneration in Men on SELECT SWOG-S0000CompletedNCT00784225Phase 3Results posted
• S0715: Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, II, or IIIA Breast Cancer Undergoing ChemoCompletedNCT00775645Phase 3Results posted
• S0801 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin LymphomaCompletedNCT00770224Phase 2Results posted
• S0722: Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By SurgeryCompletedNCT00770120Phase 2Results posted
• S0000D: Effect of Vitamin E and/or Selenium on Colorectal Polyps in Men Enrolled on SELECT Trial SWOG-S0000CompletedNCT00706121Phase 3Results posted
• S0713: Oxaliplatin, Capecitabine, Cetuximab, and RT Followed By Surgery in Pts W/Stage II or III Rectal CancerCompletedNCT00686166Phase 2Results posted

← SWOG Cancer Research Network overview and focus areas